Arcutis Biotherapeutics Inc. (ARQT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Arcutis Biotherapeutics Inc. (ARQT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How ARQT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | 90.2% | -3.3% | -$16.1M | -$6.3M | -3.8% |
| FY 2024 | $196.5M | 90.3% | -65.3% | -$140.0M | -$112.3M | -45% |
| FY 2023 | $59.6M | 44% | -404.5% | -$262.1M | -$249.7M | -14.3% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ARQT)
- ✓Live walkthrough of ARQT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ARQT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +91.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARQT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARQT. Explore sector supply chains on /butterfly.
ARQT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Arcutis Biotherapeutics Inc. (ARQT)?
In FY 2025 (10-K), ARQT converted $376.1M of revenue into a 90.2% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).